Evidence map›Paper›PMID 34761832›Full record

ArticleHead & neck2022

Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer.

Matthew E Witek, Neil M Woody, Hima B Musunuru, Patrick M Hill, Poonam Yadav, Adam R Burr, Huaising C Ko, Richard B Ross, Randall J Kimple, Paul M Harari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew E WitekDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.ORCID 0000-0003-0570-3293
Neil M WoodyDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0003-4507-6167
Hima B MusunuruDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Patrick M HillDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.
Poonam YadavDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.
Adam R BurrDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.
Huaising C KoDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.
Richard B RossCase Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
Randall J KimpleDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.ORCID 0000-0001-8336-8000
Paul M HarariDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.

Funding

Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PAUL M HARARI · 2022 to 2026
$12.5M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
NCI NIH HHS P50 CA278595NIDCR NIH HHS P50 DE026787
6 · The paper itself

Abstract

backgroundTo define the location of the initial contralateral lymph node (LN) metastasis in patients with oropharynx cancer.

methodsThe location of the LN centroids from patients with oropharynx cancer and a single radiographically positive contralateral LN was defined. A clinical target volume (CTV) inclusive of all LN centroids was created, and its impact on dose to organs at risk was assessed.

resultsWe identified 55 patients of which 49/55 had a single contralateral LN in level IIA, 4/55 in level III, 1/55 in level IIB, and 1/55 in the retropharynx. Mean radiation dose to the contralateral parotid gland was 15.1 and 21.0 Gy, (p <0.001) using the modeled high-risk elective CTV and a consensus CTV, respectively.

conclusionsWe present a systematic approach for identifying the contralateral nodal regions at highest risk of harboring subclinical disease in patients with oropharynx cancer that warrants prospective clinical study.

Indexed as

Oropharyngeal NeoplasmsRadiotherapy, ConformalHumansLymph NodesParotid GlandProspective StudiesRadiotherapy Dosageelectivelymph nodesoropharynx cancerradiotherapytoxicity

Identifiers

PMID34761832
PMCPMC9723806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.